Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain H Rook

Showing results (51-60 of 98) with videos related to

Pageof 10
Sort By:
Leukemia & Lymphoma|September 28, 2011
Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-γ: implications for therapy of cutaneous T-cell lymphomaMaria Wysocka, Noor Dawany, Bernice Benoit, et al.
Journal of the American Academy of Dermatology|September 25, 2002
Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-cell lymphomasMichael Shapiro, Mijin Yun, Jacqueline M Junkins-Hopkins, et al.
Dermatologic Therapy|December 23, 2003
The use of cytokines, fusion proteins and antibodies to treat cutaneous T-cell lymphomaAlain H Rook, Karen S McGinnis, Stephen K Richardson, et al.
Cancer Research|February 19, 2008
Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cellsMichal Marzec, Krzysztof Halasa, Monika Kasprzycka, et al.
Acta Dermato-Venereologica|March 5, 2020
Pilot Study of a Novel Therapeutic Approach for Refractory Advanced Stage Folliculotropic Mycosis FungoidesChristina A Del Guzzo, Neha N Jariwala, Paul L Haun, et al.
American Journal of Hematology|December 23, 2011
Inhibition of cell-mediated immunity by the histone deacetylase inhibitor vorinostat: implications for therapy of cutaneous T-cell lymphomaSasha Stephen, Kelly A Morrissey, Bernice M Benoit, et al.
American Journal of Hematology|September 2, 2003
Complete remission in advanced blastic NK-cell lymphoma/leukemia in elderly patients using the hyper-CVAD regimenMichael Shapiro, Mariusz A Wasik, Jacqueline M Junkins-Hopkins, et al.
Journal of the American Academy of Dermatology|October 21, 2006
A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoidesMadeleine Duvic, Matthew L Sherman, Gary S Wood, et al.
Clinical Lymphoma & Myeloma|November 21, 2007
Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12Maria Wysocka, Sarah Newton, Bernice M Benoit, et al.
Journal of the American Academy of Dermatology|August 12, 2009
Extracorporeal photopheresis: past, present, and futureRobert Knobler, Mark L Barr, Daniel R Couriel, et al.
Pageof 10

Showing results (51-60 of 98) with videos related to

Sort By:
Pageof 10
Leukemia & Lymphoma|September 28, 2011
Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-γ: implications for therapy of cutaneous T-cell lymphomaMaria Wysocka, Noor Dawany, Bernice Benoit, et al.
Journal of the American Academy of Dermatology|September 25, 2002
Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-cell lymphomasMichael Shapiro, Mijin Yun, Jacqueline M Junkins-Hopkins, et al.
Dermatologic Therapy|December 23, 2003
The use of cytokines, fusion proteins and antibodies to treat cutaneous T-cell lymphomaAlain H Rook, Karen S McGinnis, Stephen K Richardson, et al.
Cancer Research|February 19, 2008
Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cellsMichal Marzec, Krzysztof Halasa, Monika Kasprzycka, et al.
Acta Dermato-Venereologica|March 5, 2020
Pilot Study of a Novel Therapeutic Approach for Refractory Advanced Stage Folliculotropic Mycosis FungoidesChristina A Del Guzzo, Neha N Jariwala, Paul L Haun, et al.
American Journal of Hematology|December 23, 2011
Inhibition of cell-mediated immunity by the histone deacetylase inhibitor vorinostat: implications for therapy of cutaneous T-cell lymphomaSasha Stephen, Kelly A Morrissey, Bernice M Benoit, et al.
American Journal of Hematology|September 2, 2003
Complete remission in advanced blastic NK-cell lymphoma/leukemia in elderly patients using the hyper-CVAD regimenMichael Shapiro, Mariusz A Wasik, Jacqueline M Junkins-Hopkins, et al.
Journal of the American Academy of Dermatology|October 21, 2006
A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoidesMadeleine Duvic, Matthew L Sherman, Gary S Wood, et al.
Clinical Lymphoma & Myeloma|November 21, 2007
Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12Maria Wysocka, Sarah Newton, Bernice M Benoit, et al.
Journal of the American Academy of Dermatology|August 12, 2009
Extracorporeal photopheresis: past, present, and futureRobert Knobler, Mark L Barr, Daniel R Couriel, et al.
Pageof 10